RAPT Therapeutics — Investor Presentation (July 2025)
25 slides from RAPT Therapeutics's investor presentation, Jul 8, 2025
Slide 1: The Science to Overcome Inflammation – Corporate Presentation July 2025
THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JULY 2025 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected timing of clinical trials and the availability of
Slide 3: RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases
RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases RPT904 is a novel potential best-in-class half-life extended omalizumab (Xolair®) anti-IgE antibody designed for less frequent dosing and greater compliance Potential to transform treatment of Food Allergy (FA) and Chro
Slide 4: RPT904 Potential to Transform the Treatment of Food Allergy and Urticaria
RPT904 Potential to Transform the Treatment of Food Allergy and Urticaria
Slide 5: IgE is Key Driver of Allergic Reactions
SENSITIZATION PHASE EFFECTOR PHASE IgE is Key Driver of Allergic Reactions Allergen is first introduced – Immune response is initiated Captures allergen, presents it to T cells Promotes B cell development Produces IgE antibodies Th2 Cell B Cell/ Plasma Cell APC ALLERGIC REACTION Food Allergy Chronic
Slide 6: Omalizumab is Highly Effective in Reducing Allergic Reactions to Multiple Food Allergens
Omalizumab is Highly Effective in Reducing Allergic Reactions to Multiple Food Allergens OUtMATCH: Wood et al. NEJM 2024 Dosing at Q2W or Q4W based on the FA dosing table Primary End Point Key secondary End Points other secondary End Points Difference, 60 (95% CI, 47 to 70) P<0.001 Difference, 38 (9
Slide 7: Omalizumab is Highly Effective in Chronic Spontaneous Urticaria
Omalizumab is Highly Effective in Chronic Spontaneous Urticaria Results not from head-to-head trials; no direct comparisons can be made. Omalizumab 300 mg Q4W REMIBRUTINIB 25 mg BID DUPILUMAB 300 mg Q2W -11.3 -5.0 -6.3 -7.9 -6.8 -13.4 -12.6 REMIX-1 REMIX-2 RILZABRUTINIB 400 mg TID BARZOLVOLIMAB 300
Slide 8: RPT904 is a Next Generation anti-IgE Antibody with Several Potential Advantages over Omalizumab
Potential Attributes RPT904 OMA Frequency of treatment Q8/12W Q2/4W Injections per year 4-6 13-26 Available to high IgE and/or high weight (~25% of FA patients) YES NO Simplified dosing table YES NO RPT904 is a Next Generation anti-IgE Antibody with Several Potential Advantages over Omalizumab Longe
Slide 9: RPT904 Phase 1 Healthy Volunteer Data and Dose Estimations
RPT904 Phase 1 Healthy Volunteer Data and Dose Estimations
Slide 10: Jemincare Phase 1 Healthy Volunteer Study Design
Jemincare Phase 1 Healthy Volunteer Study Design Double-blind, placebo-controlled single ascending dose study of RPT904 (JYB1904) and an omalizumab comparator in healthy Chinese subjects Objectives Tolerability, safety, immunogenicity, PK and PD Route of administration Subcutaneous (SC) injection Du
Slide 11: Jemincare Phase 1 Trial Shows Longer Half-Life and Superior IgE Reduction vs Omalizumab
At 150 mg, half life for RPT904 was 60 Days vs. 26 days for omalizumab Superior free IgE reduction relative to omalizumab PD comparisons of absolute free-IgE levels to other trials not possible due to non-standard free-IgE assay format Safe and well tolerated, no ADA Jemincare Phase 1 Trial of RPT90
Slide 12: Pharmacodynamic Simulations Support Q12W Dosing In Most Patients
Pharmacodynamic Simulations Support Q12W Dosing In Most Patients *Target free IgE of 25 ng/ml ensures ≥ 95% of subjects achieve therapeutic level of < 50 ng/ml (Hochhaus et al. 2003) PK/PD projections based on published omalizumab model (Lowe, et al 2008) 25 ng/ml target free IgE* Free IgE (ng/ml) T
Slide 13: RPT904 Projected to Dose Primarily at Q12W and Treat Patients Excluded From Label
RPT904 Projected to Dose Primarily at Q12W and to Treat Patients Excluded From The Omalizumab Label for Food Allergy 8 dose strengths; 2 frequencies Q2 or Q4W (13 different regimens) ~25% of FA patients excluded from label due to high IgE/weight APPROVED OMALIZUMAB FOOD ALLERGY DOSING TABLE 3 dose s
Slide 14: RPT904 Commercial Opportunity and Positioning in FA and CSU
RPT904 Commercial Opportunity and Positioning in FA and CSU
Slide 15: Enormous Underserved Population of Food Allergy Patients In the US
Enormous Underserved Population of Food Allergy Patients In the US Datamonitor, US, 2025 (Atopic Dermatitis, Psoriasis, Rheumatoid Arthritis) ; Roche Pharma Day 2024 (Food Allergy) Patient numbers 18M 17M 8.5M 1.6M
Slide 16: Omalizumab Provides a Much-Needed Option for FA Patients
OUTMATCH Phase 3 Study Omalizumab Provides a Much-Needed Option for FA Patients Addresses multiple allergens Good tolerability and safety record Subcutaneous injections Better tolerated than OIT with similar efficacy Addresses only a single allergen Burdensome titration Adverse events reduce complia
Slide 17: Rapid Omalizumab Launch in Food Allergy Underscores High Unmet Need
Highly Rapid Omalizumab Launch in Food Allergy Underscores High Unmet Need and Expands the Market for RPT904 Atopic Dermatitis Plaque Psoriasis Food Allergy Number of Patients PATIENT VOLUME (US) Source: PharmaIntelligence epidemiology * Roche Q1 2025 Earnings >50k Patients*
Slide 18: RPT904 Has Blockbuster Potential in Food Allergy
RPT904 Has Blockbuster Potential in Food Allergy US Diagnosed Prevalence1,2 17 M 4.2 M RPT904 Share of Biologics2,7 Target Addressable Population3,4,5 Biologics Penetration6 1.7 M 1 Roche Pharma Day, 2024 2 RAPT HCP Primary Research n=140 (US n=100, UK n=40) Q4 2024 3 GlobalData, USA 4 Sindher SB, e
Slide 19: RPT904 Potential to Take Significant Share in 1st Line Position in CSU
RPT904 Potential to Take Significant Share in 1st Line Position in CSU US Diagnosed Prevalence1,2 1 M 400 K RPT904 Share of Adv. Therapies5 Target Addressable Population3,4,5 Advanced Therapy Penetration4 120 K 30% 40% 30-40% 60-70% RPT904 1 Roche Pharma Day, 2024 2 Geissbühkler et al. Adv Ther 2025
Slide 20: Payer Research Validates RPT904 For Food Allergy and CSU
Advantages vs Omalizumab Payer Research Validates RPT904 For Food Allergy and CSU 1Based on primary market research n=45 payers, Nov 2024 ; Directors of Pharmacy n=7 in-depth interviews, June 2024; Payers n=5 in-depth interviews, June 2025 Well Positioned to Be First Choice Attractive Value Proposit
Slide 21: RPT904 Clinical Development Plans
RPT904 Clinical Development Plans
Slide 22: Proposed Phase 2b Study of RPT904 Monotherapy in Food Allergy
Proposed Phase 2b Randomized Double-Blind Placebo-Controlled Study of RPT904 Monotherapy in Food Allergy Primary Endpoint: Prespecified threshold by oral food challenge N=100 (2:2:1 Q12W, Q8W regimens and placebo) US/Canada/Australia clinical sites ~18 months from FPI to topline data Treatment Exten
Slide 23: Jemincare Asthma and CSU Clinical Development Plan
Jemincare Asthma and CSU Clinical Development Plan AH: antihistamines 2025 2026 2027 2028 2029 2030 Phase 2 CSU Data Phase III CSU Start Phase III CSU Data BLA Phase 2a Asthma Data Phase III Asthma Start Phase III Asthma Data BLA Phase 2a Asthma Patients with mod-severe asthma (N=60) 3 dose levels o
Slide 24: RPT904 Anticipated Milestones
1H 2025 2H 2025 1H 2026 2H 2026 1H 2027 2H 2027 FA Phase 2b Start FA Phase 2b Topline Data CSU Phase 2 or 3 Start CSU Data (China) PK/PD Data RPT904 Anticipated Milestones Asthma Data (China)
Slide 25: Thank You
Thank You Please visit www.rapt.com
RAPT Therapeutics — Investor Presentation (July 2025) on 6ix